Clinical features of patients with HCC who are negative for both HBV and HCV markers

被引:0
|
作者
Watabe, H [1 ]
Shiratori, Y [1 ]
Tateishi, R [1 ]
Fujishima, T [1 ]
Akamatsu, M [1 ]
Koike, Y [1 ]
Obi, S [1 ]
Hamamura, K [1 ]
Sato, S [1 ]
Teratani, T [1 ]
Shiina, S [1 ]
Omata, M [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
hepatitis B; hepatitis C; hepatocellular carcinoma; liver function; alcohol; antibody to the hepatitis B core antigen; cirrhosis;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The aim of this study is to clarify the clinical features of hepatocellular carcinoma that are negative for both hepatitis B surface antigen and anti-hepatitis C antibody. Methodology: Patients were classified according to viral markers: 45 patients (8%) had hepatitis B (B-HCC), 467 patients (82%) had hepatitis C (C-HCC), and 53 patients (9%) had neither hepatitis B nor hepatitis C (NBNC-HCC). Differences in clinical parameters among these three groups were analyzed. Results: Patients with NBNC-HCC were older than B-HCC and C-HCC patients. The incidence of alcoholism in NBNC-HCC patients was higher than in C-HCC patients. Patients with NBNC-HCC had similar rates of positive antibody to hepatitis B core antigen as did patients with C-HCC. NBNC-HCC patients were further classified according to median age. The younger group showed a greater tendency towards alcoholism than did the aged group. Liver functioning in the younger group was worse than in the older. group. The older group had larger tumors than the younger group. Conclusions: The livers of younger NBNC-HCC patients were more cirrhotic, possibly because of alcoholism. Older NBNC-HCC patients presented with larger tumors, possibly because they did not receive regular medical check-ups due to their relatively preserved liver function.
引用
收藏
页码:2157 / 2160
页数:4
相关论文
共 50 条
  • [31] The factor contributing to the outcome of patients with hepatocellular carcinoma is different between HBV-associated HCC and HCV-associated HCC.
    Kobayashi, Y
    Nouso, K
    Nakamura, S
    Araki, Y
    Ikeda, H
    Takaguchi, K
    Fujio, K
    Seno, T
    Ando, M
    Kiyono, ST
    Kawaguchi, M
    Itoshima, T
    Ukida, M
    Shimamura, J
    Inoue, S
    Kita, K
    Makino, Y
    Manabe, K
    Kobashi, H
    Sakaguchi, K
    Shiratori, Y
    HEPATOLOGY, 2002, 36 (04) : 700A - 700A
  • [32] THE PATHOGENESIS OF HEPATOCELLULAR-CARCINOMA (HCC) IN ANTI-HCV POSITIVE PATIENTS - POSSIBLE IMPLICATIONS OF HBV
    OLIVERI, F
    COLOMBATTO, P
    PIANTINO, P
    CERCHIER, A
    PAPOTTI, M
    VERME, G
    BRUNETTO, MR
    BONINO, F
    HEPATOLOGY, 1993, 18 (04) : A248 - A248
  • [33] Clinical, sonographic, biochemical and histopathological assessment of hepatic steatosis in Egyptian patients with HCV and HCV associated HCC
    Elassaly, NM
    El Ray, A
    Abou Shousha, TS
    CLINICAL CHEMISTRY, 2004, 50 (06) : A188 - A188
  • [34] Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome
    Rigopoulou, Eirini I.
    Zachou, Kalliopi
    Gatselis, Nikolaos K.
    Papadamou, Georgia
    Koukoulis, George K.
    Dalekos, George N.
    WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (10) : 577 - 583
  • [35] Primary biliary cirrhosis in HBV and HCV patients:Clinical characteristics and outcome
    Eirini I Rigopoulou
    Kalliopi Zachou
    Nikolaos K Gatselis
    Georgia Papadamou
    George K Koukoulis
    George N Dalekos
    World Journal of Hepatology, 2013, (10) : 577 - 583
  • [36] Prevalence of HBV, HCV and HDV hepatitis markers in 500 HIV positive patients.
    Denis, F
    Adjide, CC
    Rogez, S
    Delpeyroux, C
    Rogez, JP
    Weinbreck, P
    PATHOLOGIE BIOLOGIE, 1997, 45 (09): : 701 - 708
  • [37] Letter: usefulness of HCC risk scores in HCV patients who fail pegylated interferon/ribavirin
    Chen, T. -M.
    Lin, C. -C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 386 - 387
  • [38] HBV RELATED AND HCV INFECTION IN HBSAG-NEGATIVE PATIENTS WITH HEPATOCELLULAR-CARCINOMA
    LIANG, TJ
    JEFFERS, LJ
    REDDY, RK
    WANDS, JR
    SCHIFF, ER
    HEPATOLOGY, 1990, 12 (04) : 881 - 881
  • [39] PATIENTS WITH CHRONIC HBV AND HCV DUAL INFECTION AND WITHOUT HBsAg SEROCLEARANCE HAD THE HIGHEST RISK FOR HCC DEVELOPMENT
    Jeng, Wen-Juei
    Pan, Mei-Hung
    Huang, Yen Tsung
    Jen, Chin-Lan
    Lu, Sheng-Nan
    Chen, Chien-Jen
    Chen, Pei-Jer
    Yang, Hwai-I
    HEPATOLOGY, 2019, 70 : 592A - 593A
  • [40] APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
    Kanda, Tatsuo
    Lau, George K. K.
    Wei, Lai
    Moriyama, Mitsuhiko
    Yu, Ming-Lung
    Chuang, Wang-Long
    Ibrahim, Alaaeldin
    Lesmana, Cosmas Rinaldi Adithya
    Sollano, Jose
    Kumar, Manoj
    Jindal, Ankur
    Sharma, Barjesh Chander
    Hamid, Saeed S.
    Dokmeci, A. Kadir
    Mamun-Al-Mahtab
    McCaughan, Geoffrey W.
    Wasim, Jafri
    Crawford, Darrell H. G.
    Kao, Jia-Horng
    Ooka, Yoshihiko
    Yokosuka, Osamu
    Sarin, Shiv Kumar
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2019, 13 (06) : 649 - 661